JP2008545703A5 - - Google Patents

Download PDF

Info

Publication number
JP2008545703A5
JP2008545703A5 JP2008513716A JP2008513716A JP2008545703A5 JP 2008545703 A5 JP2008545703 A5 JP 2008545703A5 JP 2008513716 A JP2008513716 A JP 2008513716A JP 2008513716 A JP2008513716 A JP 2008513716A JP 2008545703 A5 JP2008545703 A5 JP 2008545703A5
Authority
JP
Japan
Prior art keywords
medicament according
tissue
muscle
medicament
formulated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008513716A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008545703A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/020290 external-priority patent/WO2006130433A2/en
Publication of JP2008545703A publication Critical patent/JP2008545703A/ja
Publication of JP2008545703A5 publication Critical patent/JP2008545703A5/ja
Pending legal-status Critical Current

Links

JP2008513716A 2005-05-27 2006-05-26 幹細胞を用いた虚血の処置 Pending JP2008545703A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68561405P 2005-05-27 2005-05-27
PCT/US2006/020290 WO2006130433A2 (en) 2005-05-27 2006-05-26 Treatment of ischemia using stem cells

Publications (2)

Publication Number Publication Date
JP2008545703A JP2008545703A (ja) 2008-12-18
JP2008545703A5 true JP2008545703A5 (https=) 2009-12-17

Family

ID=37482164

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008513716A Pending JP2008545703A (ja) 2005-05-27 2006-05-26 幹細胞を用いた虚血の処置

Country Status (4)

Country Link
US (2) US8613906B2 (https=)
EP (2) EP2662439A1 (https=)
JP (1) JP2008545703A (https=)
WO (1) WO2006130433A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070298015A1 (en) * 2004-04-28 2007-12-27 Viacell, Inc. Treatment of Muscular Dystrophy with Mobilized Peripheral Blood Pluripotent Cells
GB0822246D0 (en) 2008-12-05 2009-01-14 Reneuron Ltd Composition
GB0902034D0 (en) 2009-02-06 2009-03-11 Reneuron Ltd Method
EP2625264B1 (en) 2010-10-08 2022-12-07 Terumo BCT, Inc. Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions
JP6633522B2 (ja) 2013-11-16 2020-01-22 テルモ ビーシーティー、インコーポレーテッド バイオリアクターにおける細胞増殖
WO2015148704A1 (en) 2014-03-25 2015-10-01 Terumo Bct, Inc. Passive replacement of media
US20160090569A1 (en) 2014-09-26 2016-03-31 Terumo Bct, Inc. Scheduled Feed
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
JP7034949B2 (ja) 2016-05-25 2022-03-14 テルモ ビーシーティー、インコーポレーテッド 細胞の増殖
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
CN117247899A (zh) 2017-03-31 2023-12-19 泰尔茂比司特公司 细胞扩增
TWI825446B (zh) * 2020-08-14 2023-12-11 中國醫藥大學 醫藥組合物治療組織缺血狀況之用途
GB2619893A (en) 2021-03-23 2023-12-20 Terumo Bct Inc Cell capture and expansion
US12152699B2 (en) 2022-02-28 2024-11-26 Terumo Bct, Inc. Multiple-tube pinch valve assembly
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6010696A (en) 1990-11-16 2000-01-04 Osiris Therapeutics, Inc. Enhancing hematopoietic progenitor cell engraftment using mesenchymal stem cells
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5837539A (en) 1990-11-16 1998-11-17 Osiris Therapeutics, Inc. Monoclonal antibodies for human mesenchymal stem cells
US5811094A (en) 1990-11-16 1998-09-22 Osiris Therapeutics, Inc. Connective tissue regeneration using human mesenchymal stem cell preparations
WO1994000484A1 (en) 1992-06-22 1994-01-06 Young Henry E Scar inhibitory factor and use thereof
US6054121A (en) 1993-02-26 2000-04-25 The Picower Institute For Medical Research Modulation of immune responses in blood-borne mesenchymal cells
US5804446A (en) 1993-02-26 1998-09-08 The Picower Institute For Medical Research Blood-borne mesenchymal cells
US5654186A (en) 1993-02-26 1997-08-05 The Picower Institute For Medical Research Blood-borne mesenchymal cells
US5591625A (en) 1993-11-24 1997-01-07 Case Western Reserve University Transduced mesenchymal stem cells
US5736396A (en) 1995-01-24 1998-04-07 Case Western Reserve University Lineage-directed induction of human mesenchymal stem cell differentiation
US5906934A (en) 1995-03-14 1999-05-25 Morphogen Pharmaceuticals, Inc. Mesenchymal stem cells for cartilage repair
US5908782A (en) 1995-06-05 1999-06-01 Osiris Therapeutics, Inc. Chemically defined medium for human mesenchymal stem cells
US5591444A (en) 1995-07-28 1997-01-07 Isolagen Technologies, Inc. Use of autologous dermal fibroblasts for the repair of skin and soft tissue defects
JP3781433B2 (ja) 1995-11-16 2006-05-31 ケース ウエスターン リザーブ ユニバーシティ ヒト間葉幹細胞の試験管内軟骨形成誘導
US5827740A (en) 1996-07-30 1998-10-27 Osiris Therapeutics, Inc. Adipogenic differentiation of human mesenchymal stem cells
CA2271758A1 (en) 1996-11-15 1998-05-22 Osiris Therapeutics, Inc. Msc-megakaryocyte precursor composition and method of isolating mscs associated with isolated megakaryocytes by isolating megakaryocytes
AU9127098A (en) 1997-09-04 1999-03-22 Osiris Therapeutics, Inc. Ligands that modulate differentiation of mesenchymal stem cells
US7811557B1 (en) 2000-10-27 2010-10-12 Viacell, Inc. Methods for improving central nervous system functioning
US7560280B2 (en) 2000-11-03 2009-07-14 Kourion Therapeutics Gmbh Human cord blood derived unrestricted somatic stem cells (USSC)
CA2550326A1 (en) * 2003-12-19 2005-07-14 Viacell, Inc. Use of human cord blood-derived pluripotent cells for the treatment of disease

Similar Documents

Publication Publication Date Title
JP2008545703A5 (https=)
JP2022058688A5 (https=)
ES2553742T3 (es) Forma de dosificación farmacéutica que comprende 6'-fluor-(N-metil- o N,N-dimetil)-4-fenil-4',9'-dihidro-3'H-espiro[ciclohexano-1,1'-pirano[3,4,b]indol]-4-amina
JP2014530874A5 (https=)
JP2018193377A5 (https=)
HRP20151230T1 (hr) Liksisenatid kao dodatak metforminu kod lijeäśenja dijabetesa tipa 2
JP2006525960A5 (https=)
HRP20220902T3 (hr) Pripravci i njihova upotreba u liječenju multiple skleroze
JP2013543899A5 (https=)
JP2009513660A5 (https=)
WO2009133141A3 (en) New therapeutic approaches for treating alzheimer disease and related disorders through a modulation of angiogenesis
JP2014530220A5 (https=)
JPWO2021099783A5 (https=)
AR086356A1 (es) Combinacion farmaceutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2
JP2018530592A5 (https=)
EP3276004A3 (en) Methods for treating chronic kidney disease
RU2015134581A (ru) Доноры нитроксила с улучшенным терапевтическим индексом
CL2008003201A1 (es) Composicion farmaceutica que comprende 0,5 a 50 mg de gaboxadol o una sal farmaceuticamente aceptable de este, y uno o mas inhibidores de pat1 y/o uno o mas inhibidores de oat, en donde dicha composicion brinda un perfil plasmatico in vivo con un tmax superior a 20 minutos, util en tratamientos de trastornos del sueno.
JP2013541583A5 (https=)
WO2007087241A3 (en) Treatment of ischemic disease using thrombopoietin
JP2018531929A5 (https=)
JP2021529829A5 (https=)
JP2015508765A5 (https=)
JP2008545715A5 (https=)
JP2016535780A5 (https=)